Harmony Biosciences Holdings

General Information


We are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. Our product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action, or MOA, specifically designed to increase histamine signaling in the brain by binding to H3 receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of excessive daytime sleepiness, or EDS, in adult patients with narcolepsy, and its U.S. commercial launch was initiated in November 2019. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance.

Employees: 150
Founded: 2017
Contact Information
Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, US
Phone Number (484) 539-9800
Web Address http://www.harmonybiosciences.com
View Prospectus: Harmony Biosciences Holdings
Financial Information
Market Cap $1528.3mil
Revenues $63.8 mil (last 12 months)
Net Income $-146.5 mil (last 12 months)
IPO Profile
Symbol HRMY
Exchange NASDAQ
Shares (millions): 5.4
Price range $24.00 - $24.00
Est. $ Volume $128.4 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Piper Sandler
CO-Managers -
Expected To Trade: 8/19/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change